Esophageal Cancer Drugs

Esophageal Cancer Drugs

Global Esophageal Cancer Drugs Market to Reach US$19.4 Billion by 2030

The global market for Esophageal Cancer Drugs estimated at US$12.7 Billion in the year 2023, is expected to reach US$19.4 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2023-2030. Esophageal Squamous-Cell Carcinoma Drugs, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$14.8 Billion by the end of the analysis period. Growth in the Esophageal Adenocarcinoma Drugs segment is estimated at 5.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.5 Billion While China is Forecast to Grow at 10.0% CAGR

The Esophageal Cancer Drugs market in the U.S. is estimated at US$3.5 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.2 Billion by the year 2030 trailing a CAGR of 10.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Key Trends and Drivers

Esophageal cancer is a particularly aggressive form of cancer that requires a multifaceted treatment approach, including surgery, radiation, chemotherapy, and increasingly, targeted therapy and immunotherapy. The cornerstone of drug treatment for esophageal cancer involves cytotoxic chemotherapy, which may be used in conjunction with radiation to shrink tumors before surgery or as a palliative measure in advanced cases. Recent advances have introduced targeted therapies that specifically attack cancer cells with minimal damage to normal cells. Drugs targeting the epidermal growth factor receptor (EGFR), angiogenesis inhibitors, and checkpoint inhibitors have shown promise in clinical trials, improving survival rates and offering new hope to patients with advanced esophageal cancer.

The growth in the esophageal cancer drugs market is driven by several factors, including increasing rates of esophageal cancer linked to risk factors such as smoking, obesity, and acid reflux. Advances in genomic medicine have facilitated the development of personalized treatment plans tailored to the genetic profile of individual tumors, enhancing treatment efficacy and tolerability. The approval of immunotherapeutic agents has also significantly impacted the market, providing effective options for patients who do not respond to traditional therapies. Additionally, increased investment in research and development by pharmaceutical companies and support from cancer research organizations are propelling the development of more effective treatment modalities. Lastly, growing public awareness and improving global healthcare infrastructure contribute to earlier diagnosis and treatment, further stimulating market growth.

Select Competitors (Total 35 Featured) -

• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• CStone Pharmaceuticals
• Daiichi Sankyo Co., Ltd.
• HUTCHMED
• Innovent Biologics, Inc.
• Jacobio Pharmaceuticals
• Merck & Co., Inc.
• Oncolys BioPharma
• OncoTherapy Science
• Rakuten Medical
• Shanghai Henlius Biotech
• Shanghai Junshi Biosciences
• Shionogi, Inc.
• Taiho Pharmaceutical Co., Ltd.;

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.